0001237899-19-000037.txt : 20191213 0001237899-19-000037.hdr.sgml : 20191213 20191213174352 ACCESSION NUMBER: 0001237899-19-000037 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20191211 FILED AS OF DATE: 20191213 DATE AS OF CHANGE: 20191213 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: VAGELOS P ROY CENTRAL INDEX KEY: 0001013064 STANDARD INDUSTRIAL CLASSIFICATION: AIRCRAFT [3721] STATE OF INCORPORATION: MD FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19034 FILM NUMBER: 191285434 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: REGENERON PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0000872589 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 133444607 STATE OF INCORPORATION: NY FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 777 OLD SAW MILL RIVER ROAD CITY: TARRYTOWN STATE: NY ZIP: 10591 BUSINESS PHONE: 9148477000 MAIL ADDRESS: STREET 1: 777 OLD SAW MILL RIVER ROAD CITY: TARRYTOWN STATE: NY ZIP: 10591 FORMER COMPANY: FORMER CONFORMED NAME: REGENERON PHARMACEUTICALS INC DATE OF NAME CHANGE: 19930328 4 1 edgardoc.xml PRIMARY DOCUMENT X0306 4 2019-12-11 0 0000872589 REGENERON PHARMACEUTICALS, INC. REGN 0001013064 VAGELOS P ROY 777 OLD SAW MILL RIVER ROAD TARRYTOWN NY 10591 1 1 0 0 Chairman of the Board Common Stock 2019-12-12 4 M 0 107655 21.25 A 412140 D Common Stock 2019-12-12 4 F 0 55813 377.16 D 356327 D Common Stock 2019-12-13 4 S 0 632 373.26 D 355695 D Common Stock 2019-12-13 4 S 0 6873 374.79 D 348822 D Common Stock 2019-12-13 4 S 0 21910 375.55 D 326912 D Common Stock 2019-12-13 4 S 0 13060 376.36 D 313852 D Common Stock 2019-12-13 4 S 0 5732 377.47 D 308120 D Common Stock 2019-12-13 4 S 0 3602 378.38 D 304518 D Common Stock 2019-12-13 4 S 0 33 379.14 D 304485 D Common Stock 2326 I By 401(k) Plan Common Stock 144897 I by CLAT Common Stock 83652 I by Spouse as Trustee Common Stock 1203 I by trust for grandch Non-Qualified Stock Option (right to buy) 21.25 2019-12-12 4 M 0 107655 0.0 D 2019-12-18 Common Stock 107655 0 D Non-Qualified Stock Option (right to buy) 372.46 2019-12-11 4 A 0 29177 0.0 A 2029-12-11 Common Stock 29177 29177 D Performance Stock Units 2019-12-11 4 A 0 9086 0.0 A Common Stock 9086 9086 D Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Represents volume-weighted average price of sales of 632 shares of Company stock on December 13, 2019 at prices ranging from $373.21 to $373.51. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 13, 2019 at each separate price. Represents volume-weighted average price of sales of 6,873 shares of Company stock on December 13, 2019 at prices ranging from $374.22 to $374.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 13, 2019 at each separate price. Represents volume-weighted average price of sales of 21,910 shares of Company stock on December 13, 2019 at prices ranging from $375.02 to $375.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 13, 2019 at each separate price. Represents volume-weighted average price of sales of 13,060 shares of Company stock on December 13, 2019 at prices ranging from $376.00 to $376.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 13, 2019 at each separate price. Represents volume-weighted average price of sales of 5,732 shares of Company stock on December 13, 2019 at prices ranging from $377.01 to $377.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 13, 2019 at each separate price. Represents volume-weighted average price of sales of 3,602 shares of Company stock on December 13, 2019 at prices ranging from $378.07 to $378.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 13, 2019 at each separate price. Represents volume-weighted average price of sales of 33 shares of Company stock on December 13, 2019 at prices ranging from $379.06 to $379.19. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 13, 2019 at each separate price. By a trust for the benefit of certain grandchildren of the reporting person, of which the reporting person and/or the spouse of the reporting person is trustee. The stock option award (combined incentive stock option and non-qualified stock option) vests in four equal annual installments, commencing one year after the date of grant. The stock option award vests in four equal annual installments, commencing one year after the date of grant. Each performance-based restricted stock unit ("PSU") represents the contingent right to receive one share of the issuer's common stock at vesting. The amount reported reflects the maximum number of PSUs that may vest based upon the achievement of certain performance metrics related to total shareholder return over four-year and/or five-year performance periods ending on December 11, 2023 and December 11, 2024, respectively. Between 50% and 225% of the target number of PSUs (i.e., between 50% and 225% of 4,038 PSUs) may vest upon achievement of predetermined total shareholder return percentages derived from compound annual growth rates of 5% to 15% for the applicable performance period. If none of the performance metrics are achieved at the conclusion of the performance periods, the award expires. By: Beverly Dubs, as attorney-in-fact For: P. Roy Vagelos 2019-12-13